Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)
   Google Scholar   
Citation:
Blood vol 132 (suppl 1) 151
Meeting Instance:
ASH 2018
Year:
2018
Type:
Abstract
Sub type:
Oral
Funding:
AFT
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
3304  
Program:
OGC
Primary Committee:
Myeloma
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
                         
Networks:
CA043, LAPS-AL002, LAPS-MA036, LAPS-NC007, LAPS-OH007, NC002   
Study
AFT-29 (GRIFFIN)
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: